drugset / Trial / NCT06911320

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

NCT06911320

Phase 1 Recruiting 28 enrolled Atea Pharmaceuticals, Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To Assess the Effect of Severe Hepatic or Renal Impairment on the Pharmacokinetics of Bemnifosbuvir/Ruzasvir After a Single Dose

Timeline

Start
2025-04-09
Primary completion
2026-05
Completion
2026-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Bemnifosbuvir Other / unclassified
Subject Ruzasvir Other / unclassified